Company
Every investor coverage indicates participated in a round Chimeric Therapeutics raised.
Companies Chimeric Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Chimeric Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A profile of Chimeric Therapeutics and CEO Rebecca McQualter covering its CAR T cancer therapy, clinical progress, manufacturing partnerships, FDA designations, and path to Phase 2 trials by mid-2026.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Techboard's March 2022 roundup of Australian funding: megadeals by Immutable, Saluda Medical, Linktree and Zeller, many smaller raises, acquisitions, an IPO, several fund closes, and companies still seeking capital.
Melbourne cancer immunotherapy startup Currus Biologics, spun out of Peter MacCallum, raised $10 million led by the Brandon Capital-managed Medical Research Commercialisation Fund with Uniseed, to advance its BEAT technology toward human trials.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·Startup Daily·SmartCompany·Startup Daily